Skip to main content

Rheumatoid Arthritis: Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (Reccomended for eMeasure Trial Approval)

CBE ID
2525
Endorsed
Endorsement Status
Approved for Trial Use
1.1 New or Maintenance
Maintenance
E&M Cycle
Spring 2019
Is Under Review
No
Next Planned Maintenance Review
Fall 2025
1.3 Measure Description

Percentage of patients 18 years and older with a diagnosis of rheumatoid arthritis who are newly prescribed disease modifying anti-rheumatic drug (DMARD) therapy within 12 months.

    • 1.14 Numerator

      Patient received a DMARD

    • 1.15 Denominator

      Patient age 18 years and older with a diagnosis of rheumatoid arthritis seen for two or more face-to-face encounters for RA with the same clinician during the measurement period

    • Exclusions

      Patients with a diagnosis of HIV; patients who are pregnant; or patients with inactive Rheumatoid Arthritis.

    • 1.13a Data dictionary not attached
      No
    • Most Recent Endorsement Activity
      Approved for Trial Use Primary Care and Chronic Illness Spring Cycle 2019
      Initial Endorsement
      Last Updated
    • Risk Adjustment
      No risk adjustment or risk stratification
      Risk adjustment approach
      Off
      Risk adjustment approach
      Off
      Conceptual model for risk adjustment
      Off
      Conceptual model for risk adjustment
      Off